Loading
Life sciences · Phase 2 Trial
ClinicalTrials.gov · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07873463). This is a study registration, not published results. Lead sponsor: GE Healthcare. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 20 participants (ESTIMATED). Conditions: Cognitive Dysfunction. Interventions: DRUG: GE-287; DRUG: Vizamyl; DRUG: Vizamyl; DRUG: GE-287. Primary outcome measures: Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain region , 90-100 minutes after product administration; Comparison of SUVr in posterior cingulate and precuneus brain region , 90-100 minutes after product administration; Comparison of SUVr in lateral temporal brain region , 90-100 minutes after product administration; Comparison of SUVr in inferolateral parietal brain region , 90-100 minutes after product administration; Comparison of Standard Uptake Value (SUV) in heart , 0-60 minutes after product administration; Comparison of SUV in liver , 0-60 minutes after product administration; Comparison of SUV in kidneys , 0-60 minutes after product administration. Brief summary: VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently. The aim of the study is to determine whether the new formulation works as well as the current one in identifying amyloid in the brain, how it distributes in the body, and whether it is safe for use. The study will measure how much of the study drug goes to different organs (including the brain, heart, liver, and kidneys) and monitor for any side effects.